Slioui A, Tammam G, Vanoli F, Marina A, Vohanka S, Gilhus N
Orphanet J Rare Dis. 2025; 20(1):115.
PMID: 40069719
PMC: 11895382.
DOI: 10.1186/s13023-024-03520-3.
Aguirre F, Justo M, Cialdella L, Paz M
Neurol Sci. 2024; .
PMID: 39676116
DOI: 10.1007/s10072-024-07889-8.
Sardarzada J, Anlar B
Cureus. 2024; 16(9):e68961.
PMID: 39385918
PMC: 11463899.
DOI: 10.7759/cureus.68961.
Yanai K, Takahashi S, Soejima I, Oniki A, Matsuda T, Ishihara S
Intern Med. 2024; 64(2):307-311.
PMID: 38897960
PMC: 11802234.
DOI: 10.2169/internalmedicine.3348-23.
Truffault F, Auger L, Dragin N, Vilquin J, Fadel E, de Montpreville V
Sci Rep. 2024; 14(1):13955.
PMID: 38886398
PMC: 11183198.
DOI: 10.1038/s41598-024-63162-0.
Exploring the depths of IgG4: insights into autoimmunity and novel treatments.
Unlu S, Sanchez Navarro B, Cakan E, Berchtold D, Meleka Hanna R, Vural S
Front Immunol. 2024; 15:1346671.
PMID: 38698867
PMC: 11063302.
DOI: 10.3389/fimmu.2024.1346671.
Gut microbiota-derived butyrate restores impaired regulatory T cells in patients with AChR myasthenia gravis via mTOR-mediated autophagy.
He L, Zhong Z, Wen S, Li P, Jiang Q, Liu F
Cell Commun Signal. 2024; 22(1):215.
PMID: 38570836
PMC: 10988943.
DOI: 10.1186/s12964-024-01588-9.
Mapping current trends and hotspots in myasthenia gravis from 2003 to 2022: a bibliometric analysis.
Tian Y, Shen Q, Peng S, Meng L, Fang R, Xiong A
Front Neurol. 2024; 14:1320344.
PMID: 38213833
PMC: 10782526.
DOI: 10.3389/fneur.2023.1320344.
Myasthenia gravis: the changing treatment landscape in the era of molecular therapies.
Iorio R
Nat Rev Neurol. 2024; 20(2):84-98.
PMID: 38191918
DOI: 10.1038/s41582-023-00916-w.
Pathophysiology of Childhood-Onset Myasthenia: Abnormalities of Neuromuscular Junction and Autoimmunity and Its Background.
Hayashi M
Pathophysiology. 2023; 30(4):599-617.
PMID: 38133144
PMC: 10747330.
DOI: 10.3390/pathophysiology30040043.
The Role of Thymoma and Thymic Hyperplasia as Prognostic Risk Factors for Secondary Generalisation in Adults with Ocular Myasthenia Gravis: A Systematic Narrative Review.
Wilson L, Davis H
Br Ir Orthopt J. 2023; 19(1):108-119.
PMID: 38046270
PMC: 10691285.
DOI: 10.22599/bioj.315.
Residual serum fibrinogen as a universal biomarker for all serotypes of Myasthenia gravis.
Hussain F, Piragasam R, Sarker H, Blackmore D, Yacyshyn E, Fernandez-Patron C
Sci Rep. 2023; 13(1):21229.
PMID: 38040826
PMC: 10692328.
DOI: 10.1038/s41598-023-47559-x.
Usefulness and Clinical Impact of Whole-Body MRI in Detecting Autoimmune Neuromuscular Disorders.
Pace M, Cannella R, Di Stefano V, Lupica A, Alonge P, Morici G
Brain Sci. 2023; 13(10).
PMID: 37891867
PMC: 10605918.
DOI: 10.3390/brainsci13101500.
Current Biomarker Strategies in Autoimmune Neuromuscular Diseases.
Oeztuerk M, Henes A, Schroeter C, Nelke C, Quint P, Theissen L
Cells. 2023; 12(20).
PMID: 37887300
PMC: 10605022.
DOI: 10.3390/cells12202456.
Role of complement in myasthenia gravis.
San P, Jacob S
Front Neurol. 2023; 14:1277596.
PMID: 37869140
PMC: 10585143.
DOI: 10.3389/fneur.2023.1277596.
Clinical features of myasthenia gravis with neurological and systemic autoimmune diseases.
Zhu Y, Wang B, Hao Y, Zhu R
Front Immunol. 2023; 14:1223322.
PMID: 37781409
PMC: 10538566.
DOI: 10.3389/fimmu.2023.1223322.
Balancing WNT signalling in early forebrain development: The role of LRP4 as a modulator of LRP6 function.
Geng S, Paul F, Kowalczyk I, Raimundo S, Sporbert A, Mamo T
Front Cell Dev Biol. 2023; 11:1173688.
PMID: 37091972
PMC: 10119419.
DOI: 10.3389/fcell.2023.1173688.
Serological diagnosis of myasthenia gravis and its clinical significance.
Li Y, Peng Y, Yang H
Ann Transl Med. 2023; 11(7):290.
PMID: 37090043
PMC: 10116419.
DOI: 10.21037/atm-19-363.
Transcriptional landscape of myasthenia gravis revealed by weighted gene coexpression network analysis.
Zhang D, Luo L, Lu F, Li B, Lai X
Front Genet. 2023; 14:1106359.
PMID: 37051601
PMC: 10083720.
DOI: 10.3389/fgene.2023.1106359.
Inflammation and autoimmune myasthenia gravis.
Huda R
Front Immunol. 2023; 14:1110499.
PMID: 36793733
PMC: 9923104.
DOI: 10.3389/fimmu.2023.1110499.